AU1645699A - Treatment of attention deficit hyperactivity disorder and narcolepsy - Google Patents

Treatment of attention deficit hyperactivity disorder and narcolepsy

Info

Publication number
AU1645699A
AU1645699A AU16456/99A AU1645699A AU1645699A AU 1645699 A AU1645699 A AU 1645699A AU 16456/99 A AU16456/99 A AU 16456/99A AU 1645699 A AU1645699 A AU 1645699A AU 1645699 A AU1645699 A AU 1645699A
Authority
AU
Australia
Prior art keywords
narcolepsy
treatment
attention deficit
hyperactivity disorder
deficit hyperactivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16456/99A
Other languages
English (en)
Inventor
Edward Stewart Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalent UK Swindon Encaps Ltd
Original Assignee
Catalent UK Swindon Encaps Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent UK Swindon Encaps Ltd filed Critical Catalent UK Swindon Encaps Ltd
Publication of AU1645699A publication Critical patent/AU1645699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU16456/99A 1997-07-17 1998-07-17 Treatment of attention deficit hyperactivity disorder and narcolepsy Abandoned AU1645699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9715082 1997-07-17
GB9715082A GB9715082D0 (en) 1997-07-17 1997-07-17 Treatment of attention deficit hyperactivity disorder and narcolepsy
PCT/GB1998/002124 WO1999003458A1 (fr) 1997-07-17 1998-07-17 Traitement de l'hyperactivite avec deficit de l'attention et de la narcolepsie

Publications (1)

Publication Number Publication Date
AU1645699A true AU1645699A (en) 1999-02-22

Family

ID=10816013

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16456/99A Abandoned AU1645699A (en) 1997-07-17 1998-07-17 Treatment of attention deficit hyperactivity disorder and narcolepsy

Country Status (4)

Country Link
EP (1) EP1028719A1 (fr)
AU (1) AU1645699A (fr)
GB (1) GB9715082D0 (fr)
WO (1) WO1999003458A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577623A (en) * 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3764144D1 (de) * 1986-04-16 1990-09-13 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5169868A (en) * 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
US5455276A (en) * 1993-05-20 1995-10-03 Sabelli; Hector C. Method for treating depression
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ATE241346T1 (de) * 1995-03-02 2003-06-15 Scherer Technologies Inc R P Arzneimittel enthaltend monoaminooxidase-b-hemmer
GB9504201D0 (en) * 1995-03-02 1995-04-19 Scherer Ltd R P Process for the preparation of a solid pharmaceutical dosage form
ES2180809T5 (es) * 1995-11-06 2005-06-16 Somerset Pharmaceuticals, Inc. Administracion de selegilina sublingual y bucal.

Also Published As

Publication number Publication date
GB9715082D0 (en) 1997-09-24
WO1999003458A1 (fr) 1999-01-28
EP1028719A1 (fr) 2000-08-23

Similar Documents

Publication Publication Date Title
HK1156872A1 (en) Compositions and methods for treatment of attention deficit disorder and attention deficit hyperactivity disorder with methylphenidate
EP1018987A4 (fr) Neocartilage et ses methodes d'utilisation
IL134718A0 (en) Treatment of conduct disorder
AU2402395A (en) Cancer treatment and metastasis prevention
AU9214498A (en) Treatment of attention-deficit/hyperactivity disorder
AU5811298A (en) Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
AU6435398A (en) Prevention and treatment of hepatocellular cancer
AU3035600A (en) Combination of cerivastatin and fibrates
AU5874798A (en) Vaccination methods and molecules
AU6506196A (en) Treatment of attention-deficit/hyperactivity disorder
AU3204899A (en) Hair treatment composition and method
PL332603A1 (en) Application of 1-hydroxy-2-pyridinones in treating seborrhoic dermatitis
AU1645699A (en) Treatment of attention deficit hyperactivity disorder and narcolepsy
AU6449198A (en) Biological treatment of wastewater
AU9569998A (en) Photo-spectrometers, methods of use and manufacture
AU6582698A (en) Therapeutic uses of grip and grip-related molecules
EP0927906A4 (fr) Production d'un guide d'onde plan et guide d'onde planaire
AU2080795A (en) Permeation and biological treatment of waste gas
AUPP263498A0 (en) Novel therapeutic molecules and uses therefor
ZA9811429B (en) Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate.
ZA976161B (en) Purification and enrichment of molecules.
AU8557598A (en) Treatment of fluids
SG77159A1 (en) Novel anti-clotting molecules and uses therefor
AU5611799A (en) Novel therapeutic molecules and uses therefor
AUPP551298A0 (en) Novel therapeutic molecules and uses therefor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase